Sanctuary Advisors LLC Has $1.31 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Sanctuary Advisors LLC raised its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 4.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,613 shares of the medical equipment provider’s stock after purchasing an additional 667 shares during the period. Sanctuary Advisors LLC’s holdings in Hologic were worth $1,312,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new stake in Hologic in the second quarter worth approximately $25,000. Wolff Wiese Magana LLC bought a new position in shares of Hologic during the 3rd quarter valued at $25,000. Groupama Asset Managment lifted its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 2,999 shares during the last quarter. Sunbelt Securities Inc. bought a new stake in Hologic in the second quarter worth $37,000. Finally, First Horizon Advisors Inc. increased its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 1.3 %

Shares of HOLX opened at $71.65 on Friday. The stock’s 50-day moving average price is $78.65 and its 200 day moving average price is $78.52. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. Hologic, Inc. has a 12-month low of $70.36 and a 12-month high of $84.67. The firm has a market capitalization of $16.26 billion, a price-to-earnings ratio of 21.52, a P/E/G ratio of 2.38 and a beta of 0.96.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting analysts’ consensus estimates of $1.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. During the same period in the prior year, the company posted $0.89 earnings per share. Hologic’s revenue was up 4.5% on a year-over-year basis. As a group, research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent analyst reports. UBS Group upped their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada upped their target price on Hologic from $86.00 to $89.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Mizuho dropped their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Finally, Jefferies Financial Group initiated coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $89.50.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.75% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.